Thursday February 27. 10 Biggest Gains on Thursday: Mylan ( MYL ), First Solar ( FSLR ), Cliffs Natural Resources ..... Cramer took a look at the biggest noon-time gains: 1. Mylan ( MYL ) rose more than 9%. The company recently reported
Mylan ( MYL ) Q4 2013 Earnings Call February 27, 2014 10:00 am ET Executives Kris King Heather Bresch - Chief Executive Officer, Director
(Reuters) - Shares of Mylan Inc jumped more than 10 percent on Thursday after the U.S. generic drugmaker provided a 2014 forecast above analysts' estimates and said it planned a major transaction...
Mylan 's ( MYL ) net profit rose 11% to $180.2M as double-digit growth at the company's ..... vs consensus of $3.38 and revenue of $7.8-8.2B vs $7.75B. Mylan expects to make another "substantial transaction" this year, although
Mylan Inc ( MYL ): Q4 EPS of $0.78 beats by $0.03 . Revenue of $1.81B (+5.2% Y/Y) in-line. Press Release Post your comment!
(Corrects ninth paragraph to show Forest Labs, not Mylan , as best performer on the S&P 500)
ZURICH, Feb 7 (Reuters) - Pharmaceutical group Roche said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan from comparing their copycat versions of Roche's...
Compared with its peers, Mylan 's less diversified operations increase ..... volatility in generic drug markets. Mylan faces considerable competition from ..... specialty drug segment. We estimate Mylan 's cost of capital at 9.5%.
incentive to pursue such activities, which could cut into their credit profiles going forward. On our Bonds to Avoid list, Mylan MYL (rating: BB+, narrow moat) also has incentive to pursue activities that could hurt its credit metrics, in our opinion
sales peaking in 2013 as oral drugs begin to take market share followed by two generic competitor launches, most likely Mylan and Momenta. Our base-case forecast results in Copaxone revenue below $1.0 billion by 2017. We think a handful of